Bavarian: Most compelling results so far
![Foto: Steen Wrem](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6978048.ece/ALTERNATES/schema-16_9/977788%2520-%252028_02_2003%2520-%2520Bavarian-Nordic%2520-%2520credit%2520Steen%2520Wrem.jpg)
Danish biotech company Bavarian Nordic has announced that its candidate drug Prostvac for the treatment of prostate cancer has shown great promise in a clinical trial pairing it with Bristol-Myers Squibb’s Yervoy (ipilimumab).
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Aamund: We have reached the pearly gates
For abonnenter
”You won’t hear from us until we have struck a deal”
For abonnenter
Analyst: Rival woes is positive news for Bavarian
For abonnenter